Laura Guay - Concepedia

Author

Laura Guay

Johns Hopkins University

Also Known As

Chikhungu, Norah, Eng, Eugenia, Guay, Laura, L A Guay, L Guay, L. A. Guay, L. GUAY, L. Guay, L.A. Guay, LAURA GUAY

146

Publications

7.4K

Citations

H-Index

105

Concepts

All Affiliations

Johns Hopkins University Makerere University George Washington University Elizabeth Glaser Pediatric AIDS Foundation Fred Hutch Cancer Center

About

Laura Guay is an author at Johns Hopkins University specializing in medicine, hiv, and pediatrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	27	4K
2	Education	2	2	65
3	Health Sciences	1	1	47
4	Management	1	1	62
5	Nursing	1	1	138

Laura Guay

Publications

7.1K

Citations

H-Index

Page 1

	Year	Citations
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial Laura Guay, Philippa Musoke, Thomas R. Fleming, The Lancet ContraceptionNeonatal Single-dose NevirapineTreatment And PreventionPediatricsMaternal Health	1999	1.6K
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial J. Brooks Jackson, Philippa Musoke, Thomas R. Fleming, The Lancet ContraceptionNeonatal Single-dose NevirapineHivnet 012Treatment And Prevention18-Month Follow-up	2003	523
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) Susan H. Eshleman, Martin Mracna, Laura Guay, AIDS	2001	420
Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa Elliot Marseille, James G. Kahn, Francis Mmiro, The Lancet Family MedicineContraceptionTreatment And PreventionGlobal HealthVertical Hiv-1 Transmission	1999	264
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials A Bedri, Berhanu Gudetta, Abdulhamid Isehak, The Lancet Extended-dose NevirapineSexual HealthPreventive MedicineTreatment And PreventionGlobal Health	2008	256
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006) Philippa Musoke, Laura Guay, Danstan Bagenda, AIDS	1999	215
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission J. Brooks Jackson, Graziella Becker‐Pergola, Laura Guay, AIDS	2000	212
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial Laura Guay The Lancet ContraceptionNeonatal Single-dose NevirapineTreatment And PreventionPediatricsMaternal Health	1999	200
Sensitive Drug‐Resistance Assays Reveal Long‐Term Persistence of HIV‐1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single‐Dose NVP: HIVNET 012 Tamara Flys, Dwight V. Nissley, Cassidy W. Claasen, The Journal of Infectious Diseases ImmunodeficienciesImmunologyAntiviral DrugDrug ResistanceHiv/aids Counselling	2005	188
Coreceptor Tropism in Human Immunodeficiency Virus Type 1 Subtype D: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations Wei Huang, Susan H. Eshleman, Jonathan Toma, Journal of Virology Primary ImmunodeficiencyCxcr4 TropismD Hiv-1Viral PopulationsHuman Retrovirus	2007	171

Page 1